In the short term RT's lack of hype my have hurt the SP but in the longterm, it will give the company credibility not only with the FDA but the investment community. I believe the long term benefits will far outweigh any short term pain the SP may have suffered. Sure the short term traders will disagree however RT's role is not to manage the business for the benefit of short term traders.
Ann: FDA grants Orphan for both Phelan-McDermid and Pitt Hopkins, page-20
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B | |||
| Open | High | Low | Value | Volume |
| $14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 6644 | 4 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |